China’s Biotech Drug Industry Outpaces Rest Of Asia
This article was originally published in PharmAsia News
The biotech drug industry in China has been growing by about 30 percent a year for the past two years, thanks to Chinese government efforts, industry experts say. They cite government support such as changes in regulation favorable to biopharmaceutical development. With that and its large patient population available for clinical trials, the country has become the fastest-growing in Asia in that sector, with the industry registering a 45 percent growth in sales last year. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?